Literature DB >> 12363435

Immunological aspects of controlled antigen delivery.

Shari Lofthouse1.   

Abstract

Recent advances in controlled delivery systems for protein pharmaceuticals such as microspheres, liposomes, pumps and implants, have provided a new avenue for delivery of vaccine antigens. There has, however, been considerable confusion over the way in which continuous antigen delivery affects the outcome of an immune response. To date, there has been little systematic study of the influence of varying antigen exposure times and release profiles on the phenotype of the immune response, or indeed the balance between immunity and tolerance as most studies have concentrated on optimising responses to a particular antigen of interest in a single model system. As these delivery systems would find particular advantages in management of livestock species, where the use of a single administration vaccine would significantly enhance management practices, it is important to understand the relationship between controlled antigen delivery and immunity. This paper describes how existing controlled antigen delivery studies have contributed to our understanding of the development of the immune response and demonstrates how continuous antigen delivery is useful, and possibly advantageous in the generation of immunity, the maturation of the immune response and the extension of the effector response.

Mesh:

Substances:

Year:  2002        PMID: 12363435     DOI: 10.1016/s0169-409x(02)00073-x

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  12 in total

1.  A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T-cell immunity in vivo.

Authors:  Austin Pantel; Cheolho Cheong; Durga Dandamudi; Elina Shrestha; Saurabh Mehandru; Luke Brane; Darren Ruane; Angela Teixeira; Leonia Bozzacco; Ralph M Steinman; M Paula Longhi
Journal:  Eur J Immunol       Date:  2011-12-12       Impact factor: 5.532

2.  Nanotechnology for the Development of Nanovaccines in Cancer Immunotherapy.

Authors:  Maria Aurora Grimaudo
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Tunable degradation of acetalated dextran microparticles enables controlled vaccine adjuvant and antigen delivery to modulate adaptive immune responses.

Authors:  Naihan Chen; Monica M Johnson; Michael A Collier; Matthew D Gallovic; Eric M Bachelder; Kristy M Ainslie
Journal:  J Control Release       Date:  2018-02-02       Impact factor: 9.776

4.  Antigen kinetics determines immune reactivity.

Authors:  Pål Johansen; Tazio Storni; Lorna Rettig; Zhiyong Qiu; Ani Der-Sarkissian; Kent A Smith; Vania Manolova; Karl S Lang; Gabriela Senti; Beat Müllhaupt; Tilman Gerlach; Roberto F Speck; Adrian Bot; Thomas M Kündig
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-24       Impact factor: 11.205

5.  Chitosan hydrogel vaccine generates protective CD8 T cell memory against mouse melanoma.

Authors:  Andrew J Highton; Thunjiradasiree Kojarunchitt; Adam Girardin; Sarah Hook; Roslyn A Kemp
Journal:  Immunol Cell Biol       Date:  2015-02-24       Impact factor: 5.126

6.  Vaccine adjuvants - Current status and prospects on controlled release adjuvancity.

Authors:  S M Sivakumar; Mohammed M Safhi; M Kannadasan; N Sukumaran
Journal:  Saudi Pharm J       Date:  2011-06-25       Impact factor: 4.330

7.  Immune response to controlled release of immunomodulating peptides in a murine experimental autoimmune encephalomyelitis (EAE) model.

Authors:  Hong Zhao; Paul Kiptoo; Todd D Williams; Teruna J Siahaan; Elizabeth M Topp
Journal:  J Control Release       Date:  2009-09-12       Impact factor: 9.776

Review 8.  A Quest for a Universal Plasma-Derived Antivenom Against All Elapid Neurotoxic Snake Venoms.

Authors:  Kavi Ratanabanangkoon
Journal:  Front Immunol       Date:  2021-04-23       Impact factor: 7.561

9.  Comparing the immune response to a novel intranasal nanoparticle PLGA vaccine and a commercial BPI3V vaccine in dairy calves.

Authors:  Fawad Mansoor; Bernadette Earley; Joseph P Cassidy; Bryan Markey; Simon Doherty; Michael D Welsh
Journal:  BMC Vet Res       Date:  2015-08-21       Impact factor: 2.741

10.  Archaeosomes made of Halorubrum tebenquichense total polar lipids: a new source of adjuvancy.

Authors:  Raul O Gonzalez; Leticia H Higa; Romina A Cutrullis; Marcos Bilen; Irma Morelli; Diana I Roncaglia; Ricardo S Corral; Maria Jose Morilla; Patricia B Petray; Eder L Romero
Journal:  BMC Biotechnol       Date:  2009-08-13       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.